Prelude Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Prelude Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$147K	Buy	11,040 +200	+2%	+$1.95K	0.01%	1046
2026 Q1	$101K	Sell	10,840 -4,930	-31%	-$42.9K	0.01%	1052
2025 Q4	$118K	Sell	15,770 -7,230	-31%	-$73.3K	0.01%	1159
2025 Q3	$200K	Buy	23,000 +2,300	+11%	+$13.7K	0.02%	955
2025 Q2	$76.8K	Sell	20,700 -1,800	-8%	-$6.33K	0.01%	936
2025 Q1	$72.7K	Buy	+22,500	New	+$106K	0.01%	1067
2023 Q1	–	Sell	-12,631	Closed	-$281K	–	1278
2022 Q4	$281K	Buy	+12,631	New	+$195K	0.01%	813

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Prelude Capital Management's FDMT Position: Q2 2026 in Review

Prelude Capital Management increased its 4D Molecular Therapeutics (FDMT) stake by 1.8% in Q2 2026, buying an estimated $1.95K and bringing the position to 11,040 shares worth $147K. The position accounts for 0.01% of the portfolio, ranked #1046.

Prelude Capital Management first reported a position in FDMT in Q4 2022 and has held it in 7 quarters since. The position peaked at $281K in Q4 2022. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Prelude Capital Management held 11,040 shares of 4D Molecular Therapeutics worth $147K as of Q2 2026.
Prelude Capital Management bought 200 4D Molecular Therapeutics shares in Q2 2026, an estimated $1.95K.
4D Molecular Therapeutics made up 0.01% of Prelude Capital Management's portfolio in Q2 2026, its #1046 holding.
Prelude Capital Management first reported a position in 4D Molecular Therapeutics in Q4 2022 and has held it in 7 quarters since.
Prelude Capital Management's 4D Molecular Therapeutics position peaked at $281K in Q4 2022.
157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.